Information:
Fel:
ID
12213
Beskrivning
Study of Efficacy and Safety of LJM716 and Cetuximab in Head and Neck Squamous Cell Carcinoma Patients; ODM derived from: https://clinicaltrials.gov/show/NCT02143622
Länk
https://clinicaltrials.gov/show/NCT02143622
Nyckelord
Versioner (1)
- 2015-10-18 2015-10-18 -
Uppladdad den
18 oktober 2015
DOI
För en begäran logga in.
Licens
Creative Commons BY 4.0
Modellkommentarer :
Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.
Itemgroup-kommentar för :
Item-kommentar för :
Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.
Eligibility Head and Neck Squamous Cell Carcinoma NCT02143622
Eligibility Head and Neck Squamous Cell Carcinoma NCT02143622
- StudyEvent: Eligibility
Similar models
Eligibility Head and Neck Squamous Cell Carcinoma NCT02143622
- StudyEvent: Eligibility
Name
Typ
Description | Question | Decode (Coded Value)
Datatyp
Alias
cetuximab; platinum
Item
most recent regimen contains both platinum and cetuximab (phase ii, group b).
boolean
C0995188 (UMLS CUI [1])
C0032207 (UMLS CUI [2])
C0032207 (UMLS CUI [2])
ecog performance status
Item
ecog performance status (ps) ≤ 2.
boolean
C1520224 (UMLS CUI [1])
Antineoplastic Drug/Agent Therapy
Item
recovery from all aes of previous anti-cancer therapies, to baseline or to ctcae grade ≤ 1, except for alopecia.
boolean
C2346834 (UMLS CUI [1])
measurable disease
Item
measurable disease as determined by recist v1.1.
boolean
C1513041 (UMLS CUI [1])
treatment specific antibody
Item
previous anti-her3 antibody treatment.
boolean
C0087111 (UMLS CUI [1,1])
C0443640 (UMLS CUI [1,2])
C0443640 (UMLS CUI [1,2])
symptomatic; metastasis; brain
Item
symptomatic brain metastasis.
boolean
C0231220 (UMLS CUI [1])
C0027627 (UMLS CUI [2])
C0006104 (UMLS CUI [3])
C0027627 (UMLS CUI [2])
C0006104 (UMLS CUI [3])
cancer treatment; systemic
Item
prior systemic anti-cancer treatment, within a period of time that is shorter than the cycle length used for that treatment prior to starting study treatment.
boolean
C0920425 (UMLS CUI [1])
C0205373 (UMLS CUI [2])
C0205373 (UMLS CUI [2])
allergy human immunoglobulin
Item
prior anaphylactic or other severe infusion reaction to human immunoglobulin or antibody formulations.
boolean
C0020517 (UMLS CUI [1,1])
C3537193 (UMLS CUI [1,2])
C3537193 (UMLS CUI [1,2])
Organ or Tissue Function
Item
inadequate end organ function.
boolean
C1254358 (UMLS CUI [1])
diarrhea
Item
ongoing diarrhea ctcae grade ≥ 2. other protocol-defined inclusion/exclusion criteria may apply
boolean
C0011991 (UMLS CUI [1])